Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document
- PMID: 38507182
- DOI: 10.1007/s12020-024-03773-9
Practical consensus for the treatment and follow-up of primary aldosteronism: a multidisciplinary consensus document
Abstract
Primary aldosteronism (PA) is the most frequent cause of secondary hypertension and is associated with a higher cardiometabolic risk than essential hypertension. The aim of this consensus is to provide practical clinical recommendations for its surgical and medical treatment, pathology study and biochemical and clinical follow-up, as well as for the approach in special situations like advanced age, pregnancy and chronic kidney disease, from a multidisciplinary perspective, in a nominal group consensus approach of experts from the Spanish Society of Endocrinology and Nutrition (SEEN), Spanish Society of Cardiology (SEC), Spanish Society of Nephrology (SEN), Spanish Society of Internal Medicine (SEMI), Spanish Radiology Society (SERAM), Spanish Society of Vascular and Interventional Radiology (SERVEI), Spanish Society of Laboratory Medicine (SEQC(ML)), Spanish Society of Anatomic-Pathology and Spanish Association of Surgeons (AEC).
Keywords: Adrenalectomy; Biochemical cure; Eplenerone; Hypertension; Primary aldosteronism; Spironolactone.
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
References
-
- J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889–1916 (2016). https://doi.org/10.1210/jc.2015-4061 - DOI - PubMed
-
- S. Monticone, F. D’Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41–50 (2018). https://doi.org/10.1016/S2213-8587(17)30319-4 - DOI - PubMed
-
- P. Mulatero, L.A. Sechi, T.A. Williams, J.W.M. Lenders, M. Reincke, F. Satoh et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J. Hypertens. 38, 1929–1936 (2020). https://doi.org/10.1097/HJH.0000000000002520 - DOI - PubMed
-
- G.L. Hundemer, G.C. Curhan, N. Yozamp, M. Wang, A. Vaidya, Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 6, 51–59 (2018). https://doi.org/10.1016/S2213-8587(17)30367-4 - DOI - PubMed
-
- G.P. Rossi, V. Bisogni, A.V. Bacca, A. Belfiore, M. Cesari, A. Concistrè et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int. J. Cardiol. Hypertens 5, (2020). https://doi.org/10.1016/j.ijchy.2020.100029 .
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources